Publication date: Sep 19, 2023
Clinicians and patients want to know the benefits and harms of outpatient treatment options for the Omicron variant of SARS-CoV-2. To assess the benefits and harms of 22 different COVID-19 treatments. The Epistemonikos COVID-19 L.OVE platform, the iSearch COVID-19 portfolio, and the World Health Organization (WHO) COVID-19 Research Database from 26 November 2021 to 2 March 2023. Two reviewers independently screened abstracts and full texts against a priori-defined criteria. One reviewer extracted the data and assessed the risk of bias and certainty of evidence (COE). A second reviewer verified the data abstraction and assessments. Two randomized controlled trials and 6 retrospective cohort studies were included. Nirmatrelvir-ritonavir was associated with a reduction in hospitalization due to COVID-19 (for example, 0. 7% vs. 1. 2%; moderate COE) and all-cause mortality (for example,
| Concepts | Keywords |
|---|---|
| American | American |
| Covid | Benefits |
| Outpatient | Coe |
| Physicians | College |
| Confirmed | |
| Covid | |
| Evidence | |
| Example | |
| Harms | |
| Living | |
| Outpatient | |
| Physicians | |
| Rapid | |
| Reviewer | |
| Treatment |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | COVID-19 |
| disease | VO | organization |
| drug | DRUGBANK | Ritonavir |